Key points are not available for this paper at this time.
Although chimeric antigen receptor T therapy (CAR-T) cells are an established therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models predicting outcome to identify patients who may benefit the most from CAR-T.
Gagelmann et al. (Thu,) studied this question.